Filtered By:
Specialty: Cardiology
Condition: Heart Valve Disease

This page shows you your search results in order of date.

Order by Relevance | Date

Total 185 results found since Jan 2013.

Warfarin faring better: Vitamin K antagonists beat rivaroxaban and apixaban in the INVICTUS and PROACT Xa trials
J Thromb Haemost. 2023 Jul 8:S1538-7836(23)00523-8. doi: 10.1016/j.jtha.2023.06.036. Online ahead of print.ABSTRACTAlthough guidelines give preference to the direct oral anticoagulants (DOACs) over vitamin K antagonists (VKAs) for stroke prevention in most patients with atrial fibrillation (AF), DOACs are not recommended in those with rheumatic heart disease or mechanical heart valves. The results of the INVICTUS trial (Investigation of Rheumatic AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies), which compared rivaroxaban with a VKA in patients with rheumatic heart disease associated AF, and the PR...
Source: Atherosclerosis - July 10, 2023 Category: Cardiology Authors: John W Eikelboom Jeffrey I Weitz Source Type: research

Rheumatic Heart Disease Echocardiogram Screening by Nonexperts: A Review
Rheumatic Heart Disease occurs when heart valves are damaged by Rheumatic Fever. Young First Nations Australians aged between 5 –14 years are at high risk of developing Rheumatic Fever. Complications of Rheumatic Heart Disease include atrial fibrillation, endocarditis, heart failure, and stroke. Early disease detection is essential as Acute Rheumatic Fever is easily treatable if detected early.
Source: Heart, Lung and Circulation - July 1, 2023 Category: Cardiology Authors: S. Stolic, O. Best, L. O'Malley, J. Elliott Source Type: research

Is There a Role for Vitamin K Antagonist in the Management of Atrial Fibrillation in 2023?
AbstractPurpose of ReviewTo address the following question: Are vitamin K antagonists (VKA) obsolete as stroke prevention therapy for patients with atrial fibrillation (AF) and thromboembolic risk factors?Recent FindingsA patient-level meta-analysis of the pivotal phase III randomized trials confirmed the favorable treatment effect of direct oral anticoagulants (DOAC) over VKA in multiple key patient subgroups. Among patients with AF and rheumatic heart disease (85% of whom had mitral stenosis), a randomized trial showed that rivaroxaban was not superior to VKA for stroke prevention. Caution should be exercised when prescr...
Source: Current Cardiology Reports - March 30, 2023 Category: Cardiology Source Type: research

Stroke and Noninfective Native Valvular Disease
AbstractPurpose of ReviewEmbolic stroke of undetermined source is a challenging clinical entity. While less common than atrial fibrillation and endocarditis, many noninfective heart valve lesions have been associated with stroke and may be considered as culprits for cerebral infarcts when other more common causes are excluded. This review discusses the epidemiology, pathophysiology, and management of noninfective valvular diseases that are commonly associated with stroke.Recent FindingsCalcific debris from degenerating aortic and mitral valves may embolize to the cerebral vasculature causing small- or large-vessel ischemia...
Source: Current Cardiology Reports - March 27, 2023 Category: Cardiology Source Type: research

Nationwide experience with transcarotid transcatheter aortic valve implantation: Insights from the POL-CAROTID registry
CONCLUSIONS:: The results of the study indicated that the first cohort of transcarotid transcatheter heart valves of second-generation implantations in Poland were associated with a similar prognosis to TF-TAVI with regard to safety and feasibility. TC access may be considered an optimal alternative for patients, in whom the TF approach is precluded.PMID:36594529 | DOI:10.33963/KP.a2022.0288
Source: Kardiologia Polska - January 3, 2023 Category: Cardiology Authors: Radoslaw Wilimski Zenon Huczek Kajetan Grodecki Janusz Kochman Bartosz Rymuza Wojciech Wojakowski Damian Hudziak Dariusz Jagielak Jerzy Sacha Marek Grygier Andrzej Walczak Piotr Hendzel Romuald Cicho ń Marcin Grabowski Mariusz Ku śmierczyk Source Type: research

Can Warfarin be replaced by non-vitamin K anticoagulants in prosthetic valves?
In this report, the authors discussed the published data related to NOACs use in prosthetic valves highlighting the proposed mechanisms of NOACs failure and other controversial data regarding their efficacy and safety in prosthetic valves.EXPERT OPINION: Although NOACs have proven to be even safer and more effective alternatives to vitamin K antagonists (VKAs) in several indications for anticoagulation, the data regarding their safety and efficacy in prosthetic heart valves is still debatable. The controversial data regarding NOACs use in prosthetic valves renders it difficult to define specific guideline-recommendation fo...
Source: Expert Review of Cardiovascular Therapy - November 24, 2022 Category: Cardiology Authors: Mahmoud Abdelnabi Juthipong Benjanuwattra Ashraf Ahmed Abdallah Almaghraby Source Type: research

TAVI With or Without Predilation: Trends From a Large, Propensity-Score Weighted German Aortic Valve Registry (GARY) Population
CONCLUSIONS: The safety and efficacy of d-TAVI vs b-TAVI depends on the type of THV implanted. For balloon-expandable valves, d-TAVI provides an advantage, while self-expanding valves offer a similar safety profile for d-TAVI compared with b-TAVI. However, increased mPG post intervention with both valve types and more significant PVL in self-expanding THVs emphasize the importance of proper patient selection and evaluation of valve anatomy to identify suitable cases for d-TAVI.PMID:36416901
Source: The Journal of Invasive Cardiology - November 23, 2022 Category: Cardiology Authors: Brunilda Alushi Alexander Lauten Umniye Balaban Eva Herrmann Andreas Schaefer Timm Bauer Andreas Beckmann Sabine Bleiziffer Christian Frerker Helge M öllmann Thomas Walther Raffi Bekeredjian Stephan Ensminger Lenard Conradi Source Type: research